trending Market Intelligence /marketintelligence/en/news-insights/trending/7MeZapDF1f4Y0ZMFbIzVrA2 content esgSubNav
In This List

Evofem's resubmitted nonhormonal contraceptive gel to be reviewed by US FDA

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Evofem's resubmitted nonhormonal contraceptive gel to be reviewed by US FDA

Evofem Biosciences Inc.'s resubmission for approval of nonhormonal contraceptive gel Amphora has been received by the U.S. Food and Drug Administration and given a decision date of May 25, 2020.

The San Diego-based company's second application for approval is based on phase 3 trial results that showed Amphora had an 86% efficacy rate in preventing pregnancy, Evofem said in a Dec. 18 press release.

The FDA had previously rejected Amphora in 2016 due to patient data issues.

Amphora is a gel intended to regulate vaginal pH and is also being tested to prevent sexually transmitted diseases, including gonorrhea and chlamydia.

Few new contraceptives have come to market, an issue that advisers to the FDA have pointed out. If approved, Amphora would join diaphragms, condoms and copper intrauterine devices as a nonhormonal contraceptive option for women.